We are live on ! Find out more
MTNB icon

Matinas BioPharma
MTNB

80 hedge funds and large institutions have $41.7M invested in Matinas BioPharma in 2021 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 22 increasing their positions, 14 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

83% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 12

57% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 14

13% more funds holding

Funds holding: 71 → 80 (+9)

0.02% less ownership

Funds ownership: 0.42% → 0.4% (-0.02%)

27% less capital invested

Capital invested by funds: $57.1M → $41.7M (-$15.3M)

Holders
80
Holders Change
+9
Holders Change %
+12.68%
% of All Funds
1.4%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
22
Increased
22
Reduced
14
Closed
12
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AFM
Anson Funds Management
Texas
+$4.81M
2
BlackRock
BlackRock
New York
+$1.25M
3
HF
HRT Financial
New York
+$998K
4
SIG
Sargent Investment Group
Maryland
+$777K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$407K

Top Sellers

Rank Fund Capital Flow
1
VC
Vivo Capital
California
-$8.77M
2
Renaissance Technologies
Renaissance Technologies
New York
-$1.45M
3
PFMOSF
Philadelphia Financial Management of San Francisco
California
-$1.01M
4
CIBC Private Wealth Group
CIBC Private Wealth Group
Georgia
-$816K
5
Millennium Management
Millennium Management
New York
-$549K
Name Holding Trade Value Shares
Change 		Change in
Stake
HFM
76
Hartford Financial Management
Connecticut
$3K – – –
IAIM
77
International Assets Investment Management
Florida
$3K – – –
Bank of America
78
Bank of America
North Carolina
$1K +$738 +11 New
GWMIA
79
Global Wealth Management Investment Advisory
Florida
$1K +$872 +13 New
HR
80
Howe & Rusling
New York
$1K +$1.34K +20 New
VC
81
Vivo Capital
California
– -$8.77M -129,032 Closed
PFMOSF
82
Philadelphia Financial Management of San Francisco
California
– -$1.01M -14,817 Closed
CIBC Private Wealth Group
83
CIBC Private Wealth Group
Georgia
– -$816K -12,000 Closed
Two Sigma Investments
84
Two Sigma Investments
New York
– -$130K -1,915 Closed
VF
85
Virtu Financial
New York
– -$64K -941 Closed
Man Group
86
Man Group
United Kingdom
– -$42K -623 Closed
RFC
87
Regions Financial Corp
Alabama
– -$34K -500 Closed
SPM
88
Symmetry Peak Management
Pennsylvania
– -$34K -500 Closed
EWM
89
Endurance Wealth Management
Rhode Island
– -$18K -265 Closed
Janney Montgomery Scott
90
Janney Montgomery Scott
Pennsylvania
– -$14K -210 Closed
SIAG
91
Signet Investment Advisory Group
Rhode Island
– -$1K -20 Closed
BNP Paribas Financial Markets
92
BNP Paribas Financial Markets
France
– -$34 -1 Closed
1 2 3
4

MTNB Hedge Fund Activity: Q1 2021 in Review

80 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q1 2021, worth a combined $41.7M — down 27% from $57.1M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new MTNB positions and 12 closed out — a net gain of 10 holders — while 22 added to existing stakes and 14 trimmed.

The largest buyer was Anson Funds Management, opening a new position worth an estimated $4.81M. The largest seller was Vivo Capital, exiting entirely with an estimated $8.77M sold.

  • 80 institutional investors held Matinas BioPharma (MTNB) as of Q1 2021, up from 71 in Q4 2020.
  • Funds reported $41.7M of Matinas BioPharma stock for Q1 2021, down 27% quarter-over-quarter.
  • 22 funds opened new Matinas BioPharma positions in Q1 2021 and 12 closed out, a net change of +10 holders.
  • The largest Matinas BioPharma buyer in Q1 2021 was Anson Funds Management, an estimated $4.81M added.
  • The largest Matinas BioPharma seller in Q1 2021 was Vivo Capital, an estimated $8.77M sold.

Based on aggregated 13F filings for Q1 2021.